Related Experiment Video

Updated: Aug 14, 2025

Author Spotlight: Development and Characterization of a Mouse Model for Abdominal Aortic Aneurysm
05:07

Author Spotlight: Development and Characterization of a Mouse Model for Abdominal Aortic Aneurysm

Published on: August 2, 2024

984

Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms

Zhongtiao Jin1, Hongping Deng2, Sizheng Xiong2

  • 1Master of Medicine, Department of Endocrinology, Renmin Hospital of Wuhan University, 430060, China; and.

Journal of Cardiovascular Pharmacology
|January 11, 2023
PubMed

Insights

Sodium-glucose cotransport protein inhibitors (SGLT2is) show promise for treating abdominal aortic aneurysms (AAAs). Further research is needed to explore their role as adjunct therapy or early intervention for this high-mortality condition.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Vascular Biology

Background:

  • Abdominal aortic aneurysm (AAA) incidence and mortality are rising in the elderly.
  • Current surgical and endovascular treatments have limitations in reducing future risk.
  • Effective conservative measures are needed for early intervention or adjunct therapy.

Purpose of the Study:

  • To review recent advancements in abdominal aortic aneurysm (AAA) research.
  • To explore the potential application of sodium-glucose cotransport protein inhibitors (SGLT2is) in AAA treatment.
  • To evaluate SGLT2is as an early intervention or adjunct therapy for AAA.

Main Methods:

  • Literature review of recent AAA studies.
  • Analysis of existing data on traditional AAA therapeutic agents.
  • Examination of emerging evidence for SGLT2is in cardiovascular diseases and AAA models.

Main Results:

  • Traditional agents like beta-blockers, calcium channel blockers, and statins show limited efficacy in controlling AAA growth.
  • Sodium-glucose cotransport protein inhibitors (SGLT2is) demonstrate beneficial cardiovascular effects through mechanisms like plasma volume reduction and vascular tone regulation.
  • SGLT2is are expressed in the aorta, and preliminary studies in animal models suggest therapeutic potential for AAA.

Conclusions:

  • SGLT2is represent a novel therapeutic class with potential benefits for abdominal aortic aneurysm (AAA) management.
  • Further investigation into SGLT2is is warranted for their application in early AAA intervention or as an adjunct to existing treatments.
  • The unique mechanisms of SGLT2is may offer a new conservative approach to mitigate AAA progression and improve patient outcomes.

More Related Videos

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound10:09

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound

Published on: August 4, 2022

3.3K
Biodegradable Magnesium Stent Treatment of Saccular Aneurysms in a Rat Model - Introduction of the Surgical Technique11:07

Biodegradable Magnesium Stent Treatment of Saccular Aneurysms in a Rat Model - Introduction of the Surgical Technique

Published on: October 1, 2017

11.2K

Related Concept Videos

Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
17
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
233
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
230
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
806
Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
18
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
242